Levodopa/Carbidopa Orion (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine by central aromatic L‑amino acid decarboxylase. Carbidopa blocks the same enzyme in peripheral tissues, preventing premature conversion, which raises the amount of levodopa that reaches the brain and enhances dopamine production where it is needed.

The appropriate dose is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, age, renal function, and concomitant medications. No fixed regimen can be stated; the prescriber adjusts the dose to achieve optimal symptom control while minimizing side effects.

Safety data for Levodopa/Carbidopa Orion in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified health professional.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson’s disease because it directly replenishes brain dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or early‑stage options, but they generally provide less robust motor improvement compared with the levodopa/carbidopa combination.

Store the product at temperatures below 25 °C in its original packaging. Protect it from moisture and direct sunlight. Keeping the tablets in a dry, cool environment helps maintain potency and prevents degradation over time.

Levodopa/Carbidopa Orion is taken orally, usually with a glass of water. The tablets should be swallowed whole unless the prescriber provides specific instructions to split or crush them. Dosing times are often aligned with meals to optimize absorption and reduce gastrointestinal side effects.

Serious adverse events include dyskinesia (involuntary movements), severe hypotension that can cause fainting, and neuropsychiatric effects such as hallucinations or psychosis. Patients should be monitored closely for these reactions, especially when therapy is initiated or dose adjustments are made.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective monoamine oxidase inhibitors (MAO‑I) due to the risk of hypertensive crisis, and caution is advised in those with severe cardiovascular disease or uncontrolled hypertension.